/
/
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants image
Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants
Posted Mar 22, 2021

I clearly remember the early days of my own treatment (7 years ago) for a high-risk myeloma variant. There weren’t enough hours in the day to not just compile the list of questions but to also find the answers. Sure, there were some resources available but not to the same extent as we have now, especially with the Myeloma Crowd by HealthTree and HealthTree University (Stem Cell Transplant is in Course 8). Many of those questions dealt with stem cell transplants (SCT), and I would expect that many recently diagnosed patients will also have a similar wealth of questions.

The Journal Cancers recently dedicated a special issue solely to Stem Cell Transplants in Cancer Treatment with, probably, the best survey article, titled “Role of Stem Cell Transplantation in Multiple Myeloma”, that I have seen in my years of reading journals. Even though the article was published in a medical journal it is remarkably easy to read and chances are that you will learn much of immediate potential use but also to gain a good grasp of things that are on the horizon with respect to myeloma treatment. I will not even try to summarize this article, as there is so much to digest, but just whet your appetite by listing the key topics you will find answers to:

  • Some history about SCT (always nice to know)
  • Patient eligibility in SCT for multiple myeloma
    • Patient related factors
    • Renal (kidney) insufficiency and auto SCT
    • Induction therapy 
    • Conditioning therapy
    • The role of SCT as conditioning therapy
    • Single or tandem (back-to-back) SCT 
    • Timing of auto-SCT
    • Auto-SCT as salvage therapy
    • The role of maintenance treatment after SCT
    • Allogeneic (donor) SCT
    • The role of Minimal Residual Disease (MRD) in SCT
    • There is some nice discussion in the ‘Conclusions’ section of the article about novel methods of treatment (such a CAR-T, bi-specific antibodies, different immune targets, Natural Killer (NK) cells, and others) that we will be seeing in clinical practice as time goes on.

This article is highly recommended, not just for the recently diagnosed/’new’ patients but also for those of us who already went through the SCT process, as you are bound to learn something new, here and there, that may become of value to you sometime in the future.

Additionally, consider joining our new Stem Cell Transplant Chapter to hear important topics about stem cell transplant and chat with others who have gone through the experience. Join this new chapter today! 

 

The author Paul Kleutghen

about the author
Paul Kleutghen

I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811